tirzepatide to retatrutide conversion How Switch From To Retatrutide: The Right (& Wrong) Way A Clinician's Guide to Retatrutide

92% of Symptoguard users reported reduction in nausea symptoms compared to placebo (24%) 90% of Symptoguard users would recommend it to other GLP-1 users compared to placebo (22%) 52% SymptoGuard users estimated the side effects from their GLP-1 medications were reduced by 52% 52% of Symptoguard users reported a reduction in dizziness compared to placebo (16%) 78% of Symptoguard users reported a reduction in fatigue compared to placebo (27%) These statements have not been evaluated by the Food and Drug Administration

But retatrutide isn't FDA-approved yet, and the comparison is across different trials, not a head-to-head study

Because weight management varies from person to person, getting a clear picture of a persons metabolic makeup can support an individualized approach to weight loss

doi: 10.4314/ahs.v19i3.49